Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ovid Therapeutics Inc
(NQ:
OVID
)
1.130
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ovid Therapeutics Inc
< Previous
1
2
3
Next >
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
August 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
August 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
August 01, 2024
From
The Schall Law Firm
Via
Business Wire
The Latest Analyst Ratings For Ovid Therapeutics
July 26, 2024
Via
Benzinga
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
June 18, 2024
Via
Benzinga
Ovid Therapeutics to Present at Upcoming August Investor Conferences
July 30, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
July 23, 2024
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
7 Sorry Biotech Stocks Set to Make Investors Sad
July 22, 2024
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.
Via
InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
May 07, 2024
Via
Benzinga
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
July 10, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
July 01, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
June 17, 2024
Via
Benzinga
Is the Stock Market Closed on Juneteenth 2024?
June 17, 2024
Investors wondering if the stock market is closed on Juneteenth 2024 have come to the right place as we have an answer to that question!
Via
InvestorPlace
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
June 17, 2024
Archer Aviation stock is down on Monday after the company alerted ACHR investors to a new MOU signed with Signature Aviation.
Via
InvestorPlace
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
June 17, 2024
The Aaron's Company stock is up on Monday after it announced a take-private deal that values AAN shares at $10.10 each.
Via
InvestorPlace
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
June 17, 2024
Ovid Therapeutics stock is down on Monday with heavy trading of OVID shares after the company reported a failed Phase3 clinical trial.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
June 17, 2024
Via
Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
June 17, 2024
Via
Benzinga
Exposures
Fossil Fuels
US Stocks Mixed; Dow Tumbles Over 100 Points
June 17, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
June 17, 2024
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.
Via
Benzinga
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
June 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 17, 2024
Via
Benzinga
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
June 17, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
3 Sorry Penny Stocks to Sell in May While You Still Can
May 28, 2024
Steer clear of these three penny stocks to sell that are plagued by financial instability and mounting losses.
Via
InvestorPlace
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
May 20, 2024
Although the concept of penny stocks to buy is extremely risky, these ideas have the advantage of analysts’ positive assessments.
Via
InvestorPlace
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 14, 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
May 14, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.